Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

Tempest Therapeutics (TPST) announced that the company received a “Study May Proceed” letter from the U.S. Food and Drug ...

Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of ...

REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2024 and ...

In this study, an attempt has been made to evaluate potentially significant clinical-pathologic differences in HCC's that develop in association with chronic HBV vs. HCV. Comparisons have been ...

These results suggest that VG161 has the potential to benefit heavily pre-treated HCC patients, offering a new therapeutic approach. A multicenter phase II trial assessed the combination of oncolytic ...

Macrovascular invasion (MVI) in patients with hepatocellular carcinoma (HCC) is associated with poor prognosis and limited therapeutic options. Here the authors report the results of a phase 2 ...

Finally, three other ATC patients with none of the tumor cell mutations detected in the prior two groups received atezolizumab plus bevacizumab (Avastin). Their median over survival was just over 6 ...

The following is a summary of “Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial,” ...

Treatment with regorafenib in patients with unresectable hepatocellular carcinoma and poor liver function may lead to serious side effects that may result in discontinuation of the treatment.

Our model utilized a tree-based decision analysis approach to simulate two different treatment strategies for metastatic cervical cancer: the standard bevacizumab plus platinum regimen, and the ...